Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Michelle C. Crank"'
Autor:
Sean A. Nelson, Katherine A. Richards, Maryah A. Glover, Francisco A. Chaves, Michelle C. Crank, Barney S. Graham, Masaru Kanekiyo, Andrea J. Sant
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-13 (2022)
Abstract Nanoparticle vaccines based on H. pylori ferritin are increasingly used as a vaccine platform for many pathogens, including RSV, influenza, and SARS-CoV-2. They have been found to elicit enhanced, long-lived B cell responses. The basis for i
Externí odkaz:
https://doaj.org/article/fdb8daa72b4e4c18aca6e6142b4badea
Autor:
Adrian Creanga, Rebecca A. Gillespie, Brian E. Fisher, Sarah F. Andrews, Julia Lederhofer, Christina Yap, Liam Hatch, Tyler Stephens, Yaroslav Tsybovsky, Michelle C. Crank, Julie E. Ledgerwood, Adrian B. McDermott, John R. Mascola, Barney S. Graham, Masaru Kanekiyo
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Understanding the human antibody response to influenza A virus strains is important for vaccine development. Here, Creanga et al. generate a panel of 55 replication-deficient reporter viruses representing diversity of human H1N1 and H3N2, and pandemi
Externí odkaz:
https://doaj.org/article/f356614b040e47ff842a80b70937a8bb
Autor:
Seyhan Boyoglu-Barnum, Geoffrey B. Hutchinson, Jeffrey C. Boyington, Syed M. Moin, Rebecca A. Gillespie, Yaroslav Tsybovsky, Tyler Stephens, John R. Vaile, Julia Lederhofer, Kizzmekia S. Corbett, Brian E. Fisher, Hadi M. Yassine, Sarah F. Andrews, Michelle C. Crank, Adrian B. McDermott, John R. Mascola, Barney S. Graham, Masaru Kanekiyo
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Influenza virus hemagglutinin (HA) stem between group 1 and 2 viruses has different glycosylation patterns, likely hampering cross-group protection. Here, Boyoglu-Barnum et al. show that introducing a group 2 glycan into a group 1 stem nanoparticle v
Externí odkaz:
https://doaj.org/article/341c5ca3cd954a0f92613862f3db746e
Autor:
Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood
Publikováno v:
npj Vaccines, Vol 2, Iss 1, Pp 1-6 (2017)
Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed
Externí odkaz:
https://doaj.org/article/e2d2da024d7c4739ac5a7e10fb271246
Autor:
Kizzmekia S. Corbett, Syed M. Moin, Hadi M. Yassine, Alberto Cagigi, Masaru Kanekiyo, Seyhan Boyoglu-Barnum, Sky I. Myers, Yaroslav Tsybovsky, Adam K. Wheatley, Chaim A. Schramm, Rebecca A. Gillespie, Wei Shi, Lingshu Wang, Yi Zhang, Sarah F. Andrews, M. Gordon Joyce, Michelle C. Crank, Daniel C. Douek, Adrian B. McDermott, John R. Mascola, Barney S. Graham, Jeffrey C. Boyington
Publikováno v:
mBio, Vol 10, Iss 1 (2019)
ABSTRACT Influenza vaccines targeting the highly conserved stem of the hemagglutinin (HA) surface glycoprotein have the potential to protect against pandemic and drifted seasonal influenza viruses not covered by current vaccines. While HA stem-based
Externí odkaz:
https://doaj.org/article/cd997d727dab4f9a9bff7e2660bf416f
Autor:
Lauren A. Chang, Emily Phung, Michelle C. Crank, Kaitlyn M. Morabito, Tonya Villafana, Filip Dubovsky, Judith Falloon, Mark T. Esser, Bob C. Lin, Grace L. Chen, Barney S. Graham, Tracy J. Ruckwardt
Publikováno v:
Science translational medicine. 14(676)
There is currently no licensed vaccine for respiratory syncytial virus (RSV). Here, we assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510
Autor:
Peifeng Chen, Anita Arthur, Kaitlyn M. Morabito, Kristin Leach, Xiaolin Wang, Grace L. Chen, Attila Nagy, Lauren A. Chang, Jon Cooper, Amy L. Chamberlain, Janel Holland-Linn, Olga Vasilenko, Alicia T. Widge, Shufeng Bai, Judith A Stein, LaSonji A. Holman, Cristina Carter, Iris Pittman, Deepika Gollapudi, Lisa A. Kueltzo, Colleen Fridley, Michelle C. Crank, Amritha Menon, William Whalen, Mridul Ghosh, Cynthia S. Hendel, Martha Nason, Amy Liu, Althaf Hussain, Laura Novik, Pernell Williams, Maria Burgos Florez, Robert T. Bailer, Thuy Nguyen, Brenda Larkin, Tracy J. Ruckwardt, Pamela Costner, Lam Le, Zhong Zhao, Elizabeth Carey, Vera Ivleva, Jennifer Walters, John R. Mascola, Jennifer Cunningham, Olga Trofymenko, Ya-chen Chang, Somia P. Hickman, Martin R. Gaudinski, Richard M. Schwartz, Slobodanka D. Manceva, Kevin Carlton, Barney S. Graham, Rahul Ragunathan, Jason G. D. Gall, Ana M. Ortega-Villa, Colin Tran, Sarah H. Plummer, Abidemi Ola, Ro Shauna S Rothwell, Ingelise J. Gordon, Mingzhong Chen, Jamie G. Saunders, Aba Mensima Eshun, Bob C. Lin, Azad Kumar, Nina M. Berkowitz, Xun Liu, Cora Trelles Cartagena, Emily Phung, Galina Yamshchikov, Joe Horwitz, Sarah O’Connell, Florence Kaltovich, Floreliz Mendoza, LaShawn Requilman, Man Chen, Preeti Apte, Christopher Lee, Renunda Hicks
Publikováno v:
Lancet Respir Med
Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sust
Autor:
Emily Phung, Lauren A. Chang, Maryam Mukhamedova, Lijuan Yang, Deepika Nair, Scott A. Rush, Kaitlyn M. Morabito, Jason S. McLellan, Ursula J. Buchholz, John R. Mascola, Michelle C. Crank, Grace Chen, Barney S. Graham, Tracy J. Ruckwardt
Publikováno v:
Science translational medicine. 14(650)
Respiratory syncytial virus (RSV) is a substantial cause of morbidity and mortality globally. A candidate RSV prefusion (pre-F)–stabilized subunit vaccine, DS-Cav1, has previously been shown to elicit potent and durable neutralizing activity in a p
Autor:
John R. Mascola, Sarah F. Andrews, Barney S. Graham, Tyler Stephens, Julia Lederhofer, Brian E. Fisher, Christina Yap, Yaroslav Tsybovsky, Adrian B. McDermott, Liam Hatch, Rebecca A. Gillespie, Adrian Creanga, Julie E. Ledgerwood, Masaru Kanekiyo, Michelle C. Crank
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Nature Communications
Nature Communications
Broadly neutralizing antibodies (bnAbs) have been developed as potential countermeasures for seasonal and pandemic influenza. Deep characterization of these bnAbs and polyclonal sera provides pivotal understanding for influenza immunity and informs e
Autor:
Masaru Kanekiyo, Lance Stewart, George Ueda, Rashmi Ravichandran, Nick Matheson, Miklos Guttman, Young-Jun Park, David Veesler, John R. Mascola, Syed M. Moin, Adrian Creanga, Barney S. Graham, Daniel Ellis, John R. Vaile, Deleah Pettie, Geoffrey B. Hutchinson, David Baker, Sila Ataca, Lauren Carter, Michael E. P. Murphy, Oliver J. Acton, Rebecca A. Gillespie, Michelle C. Crank, Neil P. King, Seyhan Boyoglu-Barnum, Sally Kephart, Michael J. Watson, Kelly K. Lee
Publikováno v:
Nature
Influenza vaccines that confer broad and durable protection against diverse viral strains would have a major effect on global health, as they would lessen the need for annual vaccine reformulation and immunization1. Here we show that computationally